Lack of effect of IGF-I on the glomerular filtration rate in non-diabetic patients with advanced chronic kidney disease

Growth Hormone and IGF Research

Volumn 19, Issue 3, 2009, Pages 219-225

  Kuan, Ying ^a   Surman, Joanne ^a   Frystyk, Jan ^b   El Nahas, A Meguid ^a   Flyvbjerg, Allan ^b   Haylor, John L ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Clinical Institute   (Denmark)

Author keywords

Asymmetric dimethylated arginine; Dialysis; End stage renal disease; Glomerular filtration rate; IGF Binding proteins; Recombinant human insulin like growth factor I; Tumour necrosis factor alpha

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INULIN; N(G),N(G) DIMETHYLARGININE; PLACEBO; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE PAIN; FEMALE; FLU LIKE SYNDROME; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INULIN CLEARANCE; LETHARGY; MALE; NOSE CONGESTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; THERAPY RESISTANCE; VOLUNTEER;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLACEBOS; RECOMBINANT PROTEINS; TREATMENT FAILURE;

EID: 67349259684     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.10.002     Document Type: Article

References (50)

1. Haffner D., Zacharewicz S., Mehls O., Heinrich U., and Ritz E. The acute effect of growth hormone on GFR is obliterated in chronic renal failure. Clin. Nephrol. 32 (1989) 266-269
2. Hirschberg R., Rabb H., Bergamo R., and Kopple J.D. The delayed effect of growth hormone on renal function in humans. Kidney Int. 35 (1989) 865-870
3. Guler H.P., Schmid C., Zapf J., and Froesch E.R. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc. Natl. Acad. Sci. USA 86 (1989) 2868-2872
4. Hirschberg R., Brunori G., Kopple J.D., and Guler H.P. Effects of insulin-like growth factor I on renal function in normal men. Kidney Int. 43 (1993) 387-397
5. Klinger B., and Laron Z. Renal function in Laron syndrome patients treated by insulin-like growth factor-I. Pediatr. Nephrol. 8 (1994) 684-688
6. Miller S.B., Moulton M., O'Shea M., and Hammerman M.R. Effects of IGF-I on renal function in end-stage chronic renal failure. Kidney Int. 46 (1994) 201-207
7. Ike J.O., Fervenza F.C., Hoffman A.R., et al. Early experience with extended use of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int. 51 (1997) 840-849
8. Zapf J., Hauri C., Futo E., Hussain M., et al. Intravenously injected insulin-like growth factor (IGF) I/IGF binding protein-3 complex exerts insulin-like effects in hypophysectomized, but not in normal rats. J. Clin. Invest. 95 (1995) 179-186
9. Vijayan A., Franklin S.C., Behrend T., Hammerman M.R., and Miller S.B. Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am. J. Physiol. 276 (1999) R929-934
10. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 130 (1999) 461-470
11. Dubois D D.E. A formula to estimate the approximate surface area if height and weight be known. Archiv. Int. Med. 17 (1916) 863-871
12. Kuan Y., Hossain M., Surman J., El Nahas A.M., and Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol. Dial. Transplant. 20 (2005) 2394-2401
13. Soper C.P., Bending M.R., and Barron J.L. An automated enzymatic inulin assay, capable of full sinistrin hydrolysis. Eur. J. Clin. Chem. Clin. Biochem. 33 (1995) 497-501
14. Chandra R., and Barron J.L. Anaphylactic reaction to intravenous sinistrin (Inutest). Ann. Clin. Biochem. 39 (2002) 76
15. Frystyk J., Dinesen B., and Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth. Regul. 5 (1995) 169-176
16. Frystyk J., Skjaerbaek C., Dinesen B., and Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett. 348 (1994) 185-191
17. Hirschberg R., Kopple J., Lipsett P., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 55 (1999) 2423-2432
18. Hladunewich M.A., Corrigan G., Derby G.C., et al. A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF. Kidney Int. 64 (2003) 593-602
19. O'Shea M.H., Miller S.B., and Hammerman M.R. Effects of IGF-I on renal function in patients with chronic renal failure. Am. J. Physiol. 264 (1993) F917-922
20. Vimalachandra D., Craig J.C., Cowell C.T., and Knight J.F. Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J. Pediatr. 139 (2001) 560-567
21. Maxwell H., Nair D.R., Dalton R.N., Rigden S.P., and Rees L. Differential effects of recombinant human growth hormone on glomerular filtration rate and renal plasma flow in chronic renal failure. Pediatr. Nephrol. 9 (1995) 458-463
22. Fine R.N., Stablein D., Cohen A.H., Tejani A., and Kohaut E. Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS. Kidney Int. 62 (2002) 688-696
23. Blum W.F., Ranke M.B., Kietzmann K., Tonshoff B., and Mehls O. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uraemia. Pediatr. Nephrol. 5 (1991) 539-544
24. Houang M., Cabrol S., Perin L., Ducos B., Bensman A., and Le Bouc Y. Insulin-like growth factor-I (IGF-I) insulin-like growth factor binding proteins (IGFBP) and insulin-like growth factor type I receptor in children with various status of chronic renal failure. Growth Horm. IGF Res. 10 (2000) 332-341
25. Jain S., Golde D.W., Bailey R., and Geffner M.E. Insulin-like growth factor-I resistance. Endocr. Rev. 19 (1998) 625-646
26. Frystyk J., Ivarsen P., Skjaerbaek C., Flyvbjerg A., Pedersen E.B., and Orskov H. Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. Kidney Int. 56 (1999) 2076-2084
27. Ding H., Gao X.L., Hirschberg R., Vadgama J.V., and Kopple J.D. Impaired actions of insulin-like growth factor 1 on protein synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J. Clin. Invest. 97 (1996) 1064-1075
28. Bailey J.L., Zheng B., Hu Z., Price S.R., and Mitch W.E. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J. Am. Soc. Nephrol. 17 (2006) 1388-1394
29. Ortega O., Rodriguez I., Gallar P., Carreno A., Ortiz M., Espejo B., Jimenez J., Gutierrez M., Oliet A., and Vigil A. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol. Dial. Transplant. 17 (2002) 1105-1109
30. Pereira B.J., Shapiro L., King A.J., Falagas M.E., Strom J.A., and Dinarello C.A. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45 (1994) 890-896
31. Broussard S.R., McCusker R.H., Novakofski J.E., et al. Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology 144 (2003) 2988-2996
32. Fryburg D.A. NG-monomethyl-l-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF- I: possible role of nitric oxide in muscle protein synthesis. J. Clin. Invest. 97 (1996) 1319-1328
33. Boger R.H., Skamira C., Bode-Boger S.M., Brabant G., von zur Muhlen A., and Frolich J.C. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind placebo-controlled study. J. Clin. Invest. 98 (1996) 2706-2713
34. McKillop I., Haylor J., and El Nahas A.M. IGF-I stimulates renal function in the isolated rat kidney: inhibition by aminoguanidine and nitroarginine methyl ester. Exp. Nephrol. 3 (1995) 49-57
35. Haylor J., Singh I., and El Nahas A.M. Nitric oxide synthesis inhibitor prevents vasodilation by insulin-like growth factor I. Kidney Int. 39 (1991) 333-335
36. Jaffa A.A., LeRoith D., Roberts Jr. C.T., Rust P.F., and Mayfield R.K. Insulin-like growth factor I produces renal hyperfiltration by a kinin-mediated mechanism. Am. J. Physiol. 266 (1994) F102-107
37. Lilien M.R., Schroder C.H., Levtchenko E.N., and Koomans H.A. Growth hormone therapy influences endothelial function in children with renal failure. Pediatr. Nephrol. 19 (2004) 785-789
38. Schmidt R.J., and Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 58 (2000) 1261-1266
39. Nagase S., Suzuki H., Wang Y., et al. Association of ecNOS gene polymorphisms with end stage renal diseases. Mol. Cell. Biochem. 244 (2003) 113-118
40. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
41. Casanueva F.F. Physiology of growth hormone secretion and action. Endocrinol. Metab. Clin. North Am. 21 (1992) 483-517
42. Domene H., Krishnamurthi K., Eshet R., et al. Growth hormone (GH) stimulates insulin-like growth factor-I (IGF-I) and IGF-I-binding protein-3, but not GH receptor gene expression in livers of juvenile rats. Endocrinology 133 (1993) 675-682
43. Rabkin R., Fervenza F.C., Maidment H., et al. Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure. Kidney Int. 49 (1996) 1134-1140
44. Thrailkill K.M., Quattrin T., Baker L., Kuntze J.E., Compton P.G., and Martha Jr. P.M. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM study group. Diabetes Care 22 (1999) 585-592
45. Grafe M., Bossaller C., Graf K., Auch-Schwelk W., et al. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am. J. Physiol. 264 (1993) H1493-1497
46. Napoli C., Sica V., de Nigris F., Pignalosa O., et al. Sulfydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 148 (2004) e5
47. Inishi Y., Katoh T., Okuda T., Yamaguchi T., and Kurokawa K. Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats. Kidney Int. 52 (1997) 165-170
48. McCallum R.W., Hamilton C.A., Graham D., Jardine E., Connell J.M., and Dominiczak A.F. Vascular responses to IGF-I and insulin are impaired in aortae of hypertensive rats. J. Hypertens. 23 (2005) 351-358
49. Kemp S.F. Mecasermin rinfabate. Drugs Today (Barc) 43 (2007) 149-155
50. Roelfsema V., Lane M.H., and Clark R.G. Insulin-like growth factor binding protein (IGFBP) displacers: relevance to the treatment of renal disease. Pediatr. Nephrol. 14 (2000) 584-588